Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Emerson Urology Associates","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Ludwig Enterprises","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Ludwig Enterprises

    Menu

    Ludwig Enterprises

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ludwig Enterprises

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study

              Details:

              The net proceeds will be used to fund a preclinical study on Glioblastoma (GBM), an incurable brain cancer, to potentially increase the efficacy of Merck's FDA approved drug Temodar (temozolomide).

              Lead Product(s): Temozolomide

              Therapeutic Area: Oncology Product Name: Temodar

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: University of Central florida

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing March 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ludwig Enterprises

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan

              Details:

              NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.

              Lead Product(s): Amino Acids Mixture

              Therapeutic Area: Immunology Product Name: NuGenea

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ludwig Enterprises

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study

              Details:

              Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to stimulate the immune system. BCG (mycobacterium bovis bacille calmette-guerin vaccine) has received U.S. FDA approval for the treatment of early-stage bladder cancer.

              Lead Product(s): Mycobacterium Bovis Bacille Calmette-guerin Vaccine

              Therapeutic Area: Oncology Product Name: BCG

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Emerson Urology Associates

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY